Conformation-X Therapeutics Bolts out of Stealth, Securing Over $13.5M in Funding to Propel Its Innovative Immune-Oncology Pipeline
3.4.2024 13:55:00 EEST | Business Wire | Press release
Conformation-X Therapeutics, LLC, an immune-oncology focused drug development company, announced today that it has closed an oversubscribed funding tranche of $3.65M, bringing the total raised since inception to over $13.5M. The company unveiled its lead assets by disclosing successful ex vivo and in vivo proof-of-concept studies for its HHLA2 and IL18BP programs, marking critical milestones in the cancer drug development process.
Drawing inspiration from the fundamental role of protein conformations in disease biology and drug efficacy, Conformation-X applies unparalleled precision to developing novel immune checkpoint inhibitors. The company is creating a comprehensive portfolio of differentiated therapeutics addressing cancer mechanisms that have eluded existing treatments.
“The limitations of current checkpoint therapies are evident, as they don’t fully target the diverse spectrum of mechanisms associated with non-responsiveness and treatment resistance,” said Dr. Ali H. Munawar, CEO of Conformation-X Therapeutics.
Despite the pivotal role of PD-1/PD-L1 inhibitors in cancer immunotherapy, several peer-reviewed clinical studies have shown that the overall response rate across various cancers remains at or below 20%. Patients facing resistance to conventional checkpoint therapies encounter a range of challenges. This includes tumors that inherently possess low immunogenicity, are less likely to trigger an immune response, and immune exclusion, which restricts immune cells from the tumor microenvironment (TME). Moreover, complex genetic landscapes featuring oncogenic drivers and epigenetic modifications further contribute to immune evasion and influence treatment outcomes.
Dr. Munawar added, “We are committed to pioneering alternative therapeutic options for these patients by targeting novel biology and molecular pathways. The successive rounds of funding are a testament to our investors’ confidence in the innovation and rigor behind our efforts.”
The recent capital infusion accelerates the company towards translational studies of its lead asset and facilitates the expansion of its pipeline. The company's pipeline encompasses diverse drug target classes, extending beyond the current landscape of immune checkpoints to include novel soluble and epigenetic checkpoints while continuing to innovate within the B7-family of receptors.
“Achieving selective therapeutic targeting of HHLA2 demonstrates our team’s profound understanding of its intricate structure-function relationship and the critical role that HHLA2 plays in tumor immune evasion. Our work highlights the strength of Conformation-X’s drug discovery platform,” said Dr. Stephen Weeks, Sr. Director of Structural Biology and Biophysics.
About Conformation-X Therapeutics
Conformation-X utilizes a proprietary discovery platform enriched by structural insights to pioneer therapeutics with innovative mechanisms of action. The company is developing a diverse portfolio of immunotherapies that activate both the innate and adaptive arms of the immune system. The company’s premier preclinical asset includes a potent HHLA2-inhibitor that selectively restores its immune-suppressing effect with application in PD1/PDL1-negative cancers. To learn more visit www.conformationx.com.
Conformation-X Therapeutics is an independent, privately held research & development (R&D) company affiliated with the Pledge Therapeutics discovery platform.
About Pledge Therapeutics
Pledge Therapeutics is headquartered in Greater Boston with a second R&D branch in Leuven, Belgium. Pledge harnesses a state-of-the-art platform that merges structure-based drug design with biophysics, facilitating breakthroughs in the design of treatments for challenging therapeutic targets.
Pledge is grounded in a collaborative ethos, drawing on a network of experienced life sciences entrepreneurs, clinicians, and discovery scientists. Under its management umbrella, Pledge unites two independent biotech ventures: Orthogon Therapeutics, which specializes in antiviral treatments, and Conformation-X, dedicated to advancements in immune-oncology. This integrated model reinforces Pledge’s mission to revolutionize patient care across diverse therapeutic areas. More info on www.pledge-tx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403623298/en/
Contact information
Media
Ali H. Munawar, Ph.D.
amunawar@conformationx.com
1-339-502-8643
Maria Martin
mmartin@pledge-tx.com
1-339-502-8630
Krishna Kandala
kkandala@pledge-tx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lyft App Launches in Europe30.9.2026 15:00:00 EEST | Press release
Starting today, Lyft (NASDAQ: LYFT) riders can use their Lyft app in cities across Europe. Early access to the Lyft app rolls out in Barcelona and Hamburg first; throughout October, the Lyft app will become available for riders to use in some of Europe’s largest cities including London, Rome, Paris, Berlin, Athens, and Warsaw. By the end of October riders visiting Spain, Italy, Greece, Poland, England, Scotland, Ireland, Austria, France, and Germany will have one go-to app when they cross the Atlantic, building on the foundations from this past summer beta testing the Lyft app in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930010726/en/ The Lyft app is now available in Europe “Millions of riders across North America trust Lyft to get them where they’re going every day. Now that same app works the moment they land in Europe. No need to download anything new,” said Sid Patil, Lyft’s Chief Rideshare and Marketplac
A Workplace Worth Toasting: Bacardi Continues its Rise on Forbes World’s Best Employers List30.9.2026 14:45:00 EEST | Press release
Bacardi Limited is proving that a workplace worth toasting keeps getting better. The family-owned business has once again been named to the Forbes World's Best Employers list, taking the top spot among spirits companies. Climbing 17 places since last year, in 2026 Bacardi comes in at #69 globally. The jump in ranking reflects a commitment to creating a workplace where employees feel valued, empowered, and inspired to grow while helping shape the future of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930327935/en/ Bacardi Limited Leads Spirits Companies Forbes World's Best Employers 2026 Ranking. “At Bacardi, great moments start with great people. That's why we listen carefully to what they're telling us, learn from that feedback, and keep evolving. We want people to feel clear on how they can grow, confident they can make their mark, and supported to do their best work,” says Dave Ingram, Chief People and T
Forrester’s 2027 European Predictions: Despite A Strong Desire To Regain Its Digital Sovereignty, Europe Will Selectively Reset, Not Sever, Key Technology Relationships30.9.2026 14:33:00 EEST | Press release
According to Forrester’s (Nasdaq: FORR) 2027 European predictions, unveiled today at Forrester’s Technology & Innovation Forum EMEA, Europe will enter 2027 determined to recover its digital autonomy, but the gap between its ambition and control will widen. More than half of European companies embracing AI will reduce their dependence on US hyperscalers due to sovereignty concerns, moving their critical data and applications to European providers. A lack of end-to-end sovereign alternatives, however, will require consumers, companies, and policymakers to pursue selective digital autonomy, which consequently will reshape consumer behaviours, cloud choices, mobility, resilience, and trade strategy with China. Forrester’s Predictions reports offer forward-looking insights into trends to help executives and their teams anticipate change, reduce uncertainty, and make confident decisions ahead of market shifts. Key highlights from the Europe 2027 predictions include: China will trigger manufa
Vasion® Named a Leader in the 2026 IDC MarketScape for Worldwide Print Management Solutions as Enterprise Print Becomes AI Ready30.9.2026 14:30:00 EEST | Press release
Vasion, the intelligent print automation company, today announced it has been named a Leader in the IDC MarketScape for Worldwide Print Management Solutions 2026 Vendor Assessment (doc # US54124826, September 2026). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930788016/en/ According to the IDC MarketScape, "Organizations in sectors such as education, healthcare, government, manufacturing, financial services, and retail should consider Vasion when seeking support for business process automation revolving around print, output, and agentic or rules-based workflows. Vasion customers may derive considerable value from the vendor's solutions in support of unifying their organizations' digital transformation efforts, particularly where a single portal with functionality extending beyond print management is sought, and especially where FedRAMP® High Authorization, a SOC 2 Type II report, or ISO 27001/42001 certification is req
Pantheon Expands Middle East Presence With New Abu Dhabi Office and Senior Regional Appointment30.9.2026 13:56:00 EEST | Press release
Pantheon, a leading global private markets firm with approximately $84bn in assets under management, today announced the expansion of its presence in the Middle East with the opening of its first office in ADGM, the international financial center based in Abu Dhabi, alongside the appointment of Firas Mallah as Managing Director and Head of Middle East. Demand for access to private equity, infrastructure, and private credit strategies continues to build among sophisticated investors across the Middle East, who recognize Pantheon for its 40-year track record of innovation and expertise across primaries, secondaries and co-investment opportunities. Secondaries – pioneered by Pantheon in 1988 – remains a defining thread across the platform: alongside its long-established private equity secondaries business, Pantheon has among the industry's first and largest private credit and infrastructure secondaries franchises, making it a strong partner in that space across the GCC. These strategies a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom